Loading
A phase 2 trial of Retifanlimab in head and neck squamous cell carcinoma, run by Incyte Biosciences International Sàrl, active and no longer recruiting.
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck is a phase 2 interventional study registered as NCT05287113 by Incyte Biosciences International Sàrl, with 176 participants enrolled, started 2022-11-14 and due to reach its primary completion in 2025-03-14. Interventions recorded: Retifanlimab, INCAGN02385, INCAGN02390 and Placebo. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
176 enrolled.
95% CI 3.5 to 9.7; Figures from the ClinicalTrials.gov results section (first posted 2026-03-27), not from a publication · 95% CI 3.7 to 7.6 · 95% CI 2.1 to 7.9
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progeression-free Survival (PFS)primary | Retifanlimab | 59 | 5.6 months | - | - | link |
| Retifanlimab Plus INCAGN02385 | 60 | 5.8 months | ||||
| Retifanlimab Plus INCAGN02385 Plus INCAGN02390 | 57 | 5.3 months |
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma, Immune checkpoint inhibitors and the tag pipeline.
Shares Incyte, Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma, Immune checkpoint inhibitors and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Retifanlimab and the tag pipeline.
Shares Incyte and the tag pipeline.